Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 19/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529368 | 0.91 | CETP (0.69) | CETP | |
| SCHEMBL13212503 | 0.81 | CETP (0.66) | CETP | |
| SCHEMBL23977184 | 0.81 | CETP (0.77) | CETP | |
| SCHEMBL1524975 | 0.81 | CETP (0.73) | CETP | |
| SCHEMBL13212520 | 0.80 | CETP (0.64) | CETP | |
| SCHEMBL23987640 | 0.80 | CETP (0.76) | CETP | |
| SCHEMBL23977229 | 0.80 | CETP (0.76) | CETP | |
| SCHEMBL1524573 | 0.80 | CETP (0.71) | CETP | |
| SCHEMBL23976941 | 0.80 | CETP (0.76) | CETP | |
| SCHEMBL23976943 | 0.80 | CETP (0.76) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | claimed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | claimed |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2019-03-07 | — | — | US | claimed |
| US-20180049997-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2018-02-22 | — | — | US | claimed |
| US-20150374675-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2015-12-31 | — | — | US | claimed |
| US-20140309426-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTRÉAL (CA) | 2014-10-16 | — | — | US | claimed |
| US-20140243414-A1 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2014-08-28 | — | — | US | claimed |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2013-08-01 | — | — | US | claimed |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2013-02-28 | — | — | US | claimed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | claimed |
| US-20080027109-A1 | bis-[2-(pivaloylamino)phenyl]disulfide; cholesteryl ester transfer protein (CETP); atherosclerosis, hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2008-01-31 | — | — | US | claimed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| EP-1710231-A1 | CETP activity inhibitors | Japan Tobacco, Inc. (JP) | 2006-10-11 | — | — | EP | claimed |
| EP-1020439-B1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC (JP) | 2006-08-30 | — | — | EP | claimed |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | US | claimed |
| US-20040225018-A1 | administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal | JAPAN TOBACCO INC. (JP) | 2004-11-11 | — | — | US | claimed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | claimed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | claimed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309426-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | CETP 5/4885 |
| US-20080027109-A1 | bis-[2-(pivaloylamino)phenyl]disulfide; cholesteryl ester transfer protein (CETP); atherosclerosis, hyperlipidemia | CETP, MTTP, APOB | CETP 1/4885 |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | CETP, MTTP, LCAT | CETP 1/4885 |
| US-20150374675-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | CETP 5/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CETP 1/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | CETP 311/4885 |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CETP 1/4885 |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | CETP, PCSK9, LCAT | CETP 1/4885 |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | CETP 5/4885 |
| US-20140243414-A1 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | CETP, NPC1L1, LCAT | CETP 1/4885 |
| US-20180049997-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | CETP, LCAT, MTTP | CETP 1/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | CETP 1/4885 |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | CETP 10/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | CETP 10/4885 |
| US-20040225018-A1 | administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal | CETP, MTTP, PCTP | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.